Compare QSI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | ENTX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 147.4M |
| IPO Year | N/A | 2015 |
| Metric | QSI | ENTX |
|---|---|---|
| Price | $0.76 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.00 | ★ $9.00 |
| AVG Volume (30 Days) | 2.7M | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | N/A |
| P/E Ratio | ★ N/A | $41.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $0.91 |
| 52 Week High | $3.10 | $4.20 |
| Indicator | QSI | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 60.29 |
| Support Level | $0.69 | $1.26 |
| Resistance Level | $1.11 | $3.22 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 45.31 | 40.43 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.